|This article needs additional citations for verification. (January 2010)|
|Classification and external resources|
Metachromatic leukodystrophy (MLD, also called Arylsulfatase A deficiency) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of sphingolipids. Leukodystrophies affect the growth and/or development of myelin, the fatty covering which acts as an insulator around nerve fibers throughout the central and peripheral nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most enzyme deficiencies, has an autosomal recessive inheritance pattern.
MLD is directly caused by a deficiency of the enzyme arylsulfatase A (ARSA) and is characterized by enzyme activity in leukocytes that is less than 10% of normal controls. However, assay of the ARSA enzyme activity alone is not sufficient for diagnosis; ARSA pseudodeficiency, which is characterized by enzyme activity that is 5~20% of normal controls does not cause MLD. Without this enzyme, sulfatides build up in many tissues of the body, eventually destroying the myelin sheath of the nervous system. The myelin sheath is a fatty covering that protects nerve fibers. Without it, the nerves in the brain (central nervous system - CNS) and the peripheral nerves (peripheral nervous system - PNS) which control, among other things the muscles related to mobility, cease to function properly.
Arylsulfatase A is activated by Saposin B (Sap B), a non-enzymatic proteinaceous cofactor. When the Arylsulfatase A enzyme level is normal but the sulfatides are still high - meaning that they are not being broken down because the enzyme is not activated the resulting disease is Saposin B Deficiency. Saposin B Deficiency is very rare, much more rare than traditional MLD. The enzyme that is present is not "enabled" to a normal level of efficiency and can't break down the sulfatides which results in all of the same MLD symptoms and progression. - See more at: http://mldfoundation.org/MLD-101-genetics.html
A recent study contended sulfatide is not completely responsible for MLD because it is nontoxic. It has been suggested lysosulfatide, sulfatide which has had its acyl group removed, plays a role because of its cytotoxic properties in vitro.
MLD has an autosomal recessive inheritance pattern. The inheritance probabilities per birth are as follows:
- If both parents are carriers:
- 25% (1 in 4) children will have the disease
- 50% (2 in 4) children will be carriers, but unaffected
- 25% (1 in 4) children will be free of MLD - unaffected child that is not a carrier
- If one parent is affected and one is free of MLD:
- 0% (0) children will have the disorder - only one parent is affected, other parent always gives normal gene
- 100% (4 in 4) children will be carriers (but unaffected)
- If one parent is a carrier and the other is free of MLD:
- 50% (2 in 4) children will be carriers (but unaffected)
- 50% (2 in 4) children will be free of MLD - unaffected child that is not a carrier
In addition to these frequencies there is a 'pseudo'-deficiency that affects 7%-15% of the population. People with the pseudo deficiency do not have any MLD problems unless they also have affected status. With the current diagnostic tests, Pseudo-deficiency reports as low enzyme levels but sulfatide is processed normally so MLD symptoms do not exist. This phenomenon wreaks havoc with traditional approaches to Newborn Screening so new screening methods are being developed.
The incidence of metachromatic leukodystrophy is estimated to occur in 1 in 40,000 to 1 in 160,000 individuals worldwide. There is a much higher incidence in certain genetically isolated populations, such as 1 in 75 in Habbanites (a small group of Jews who immigrated to Israel from southern Arabia), 1 in 2,500 in the western portion of the Navajo Nation, and 1 in 8,000 among Arab groups in Israel.
Symptoms and forms
- In the late infantile form, which is the most common form of MLD (50-60%), affected children begin having difficulty walking after the first year of life, usually at 15–24 months. Symptoms include muscle wasting and weakness, muscle rigidity, developmental delays, progressive loss of vision leading to blindness, convulsions, impaired swallowing, paralysis, and dementia. Children may become comatose. Untreated, most children with this form of MLD die by age 5, often much sooner.
- Children with the juvenile form of MLD (onset between 3 and 10 years of age) usually begin with impaired school performance, mental deterioration, and dementia and then develop symptoms similar to the late infantile form but with slower progression. Age of death is variable, but normally within 10 to 15 years of symptom onset although some juveniles can live for several decades or longer after onset.
- The adult form commonly begins after age 16 as a psychiatric disorder or progressive dementia. Adult-onset MLD progresses more slowly than the late infantile and juvenile forms, with a protracted course of a decade or more.
Palliative care can help with many of the symptoms and usually improves quality of life and longevity.
Carriers have low enzyme levels compared to their family population ("normal" levels vary from family to family) but even low enzyme levels are adequate to process the body's sulfatide.
There is currently no treatment or cure for MLD. Children with advanced juvenile or adult onset and late infantile patients displaying symptoms receive treatment limited to pain and symptom management. Presymptomatic late infantile MLD patients, as well as those with juvenile or adult MLD that are either presymptomatic or displaying mild to moderate symptoms, have the option of bone marrow transplantation (including stem cell transplantation), which is under investigation to see if it may slow down progression of the disease or stop its progression in the central nervous system. However, results in the peripheral nervous system have been less dramatic, and the long-term results of these therapies have been mixed.
Several future treatment options are currently being investigated. These include gene therapy, enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and potentially enzyme enhancement therapy (EET).
A team of international researchers and foundations organized in 2008 to form an International MLD Registry to create and manage a shared repository of knowledge, including the natural history of MLD. This consortium consists of scientific, academic and industry resources. This registry never became operational.
Bone marrow and stem cell transplant therapies
- Several trials are underway to continue to improve the effectiveness and reduce the risks of bone marrow and stem cell transplants. Cord blood transplants and reduced preparative routines are being studied.
Two different approaches to gene therapy are currently being researched for MLD.
- Gene therapy with an autologous stem cell transplant - Italian researchers at the San Raffaele Telethon Institute tested a novel approach combining gene therapy with a stem cell transplant. Recruiting for the Phase I/II Clinical Trial formally started on March 24, 2010 after approval from the Italian Authorities. Recruiting the initial cohort of 8 patients was completed in mid-March 2013. The trial was to test the efficacy and safety of autologous (using the patient's own cells) hematopoietic stem cell transplantation (HSCT) after genetic modification to deliver a super-therapeutic (over-expressing) ARSA enzyme to the nervous system by the route of the blood cells. Using the patient's own stem cells with genetic correction should reduce or eliminate the complications of graft vs. host disease and provide a long term solution to proper ARSA expression in MLD patients. Bench and animal tests showed positive results. The researchers published 2-year outcomes for the first three patients in July 2013. Results were described as promising.
- In December 2014, the protocol was amended to include 6 more patients, netting a total of 20 to be treated during the initial Phase I/II trial period.
- Inclusion criteria are pre-symptomatic late infantiles and both pre- and early-symptomatic juveniles. See details on inclusion criteria and the trial protocol here.
- The trial was single center in Milan, Italy. All costs were to be paid by the researchers. This was a 3-year study. In March 2013, the last of the 8 primary trial patients started therapy. A limited compassionate access period is underway.(Current June 2014)
- In late 2013 GSK exercised its option for the San Rafaelle gene therapy technology and is working with the Milan Investigators to prepare for the next phase of study.
- Intracerebral Gene therapy - A Phase I/II Clinical Trial started recruiting in Paris in late March, 2013 for an Intracerebral Gene Therapy clinical trial where special "vectors" carrying genetically modified material are directly injected into a dozen sites in the brain. The hope is that the corrected cells and the enzyme they produce will then diffuse into surrounding areas of the brain. Extensive work in the lab and some encouraging ALD studies provided the basis for this trial.
- Recruiting 5 late infantiles between the ages of 6 and 48 months for a two-year study
- Must have first shown symptoms in the last 12 months
- Additional trial inclusion criteria and information can be found here
Enzyme replacement therapy (ERT)
(current as of June 2014)
- Shire (formerly known as Shire HGT-Human Genetic Therapies ), a division of Shire PLC of the UK, started recruiting for their clinical trial for their intrathecal HGT-1110 ERT product January, 2012
- Trial Centers
- Trial centers were opened in Europe, South America and Australia
- Patients were successfully recruited in all trial centers
- The Phase I/II trial was fully recruited in May of 2014.
- Inclusion Criteria
- The clinical trial is a 38 week multi-site study of 18 children in three different dosing cohorts. The 'no treatment' placebo arm was removed from the trial in June 2012.
- Patients must go to one of five trial sites for their every other week enzyme infusions: Copenhagen Denmark, Paris France, Tübingen Germany, Sydney Australia, or Porto Alegre Brazil. Derqui, Argentina is awaiting approval.
- A new intrathecal port from a new vendor was approved for use starting December 2013. See the MLD Foundation website for more details.
- HGT-1110 has orphan product status in both Europe and the United States.
- History: Shire suspended development of the Metazyme intravenous ERT product in 2010. It was in clinical trial when it was acquired from Zymenex in 2008 (subsequently renamed HGT-1111 by Shire) after it was shown to not have sufficient efficacy by a Phase I/II clinical trial in Europe. The initial study completed September 2008 and the extension study completed October 2010 with the cessation of product supply to trial participants.
- Trial Centers
Substrate reduction therapy
- Biomarin South (formerly Zacharon before being acquired by Biomarin in January 2013) from San Diego has initiated a drug discovery program for MLD. This program is based on using assays which measure sulfatide accumulation in cultured fibroblasts as a means to discover and develop small molecule drugs for MLD. (This approach differs from other approaches which have measured enzyme activity to discover effective drugs.) As of July 2011, Zacharon has begun adapting the assays it developed for other lysosomal storage diseases so that they can be employed to discover and develop drugs for MLD. (current March 2013)
- The Cooper Health System (New Jersey) sponsored a clinical trial underway to determine the safety and efficacy of a Vitamin K antagonist (Warfarin) in treating Metachromatic Leukodystrophy (MLD) in 2009. No results are known to have been published. (current March 2013)
Natural History Studies
- A natural history study has been underway in Pittsburgh, PA since November 2012.
- A separate and different NHS launched in Washington, DC in January of 2014 with subsequent study centers in Chicago and Los Angeles.
more information here (current June 2014)
Research & Clinical Trial updates provided by the MLD Foundation
- "metachromatic leukodystrophy" at Dorland's Medical Dictionary
- Le, Tao; Bhushan, Vikas; Hofmann, Jeffrey (2012). First Aid for the USMLE Step 1. McGraw-Hill. p. 117.
- Poeppel P, Habetha M, Marcão A, Büssow H, Berna L, Gieselmann V (March 2005). "Missense mutations as a cause of metachromatic leukodystrophy, Degradation of arylsulfatase A in the endoplasmic reticulum". FEBS J. 272 (5): 1179–88. doi:10.1111/j.1742-4658.2005.04553.x. PMID 15720392.
- Fluharty, Arvan. "Arylsulfatase A Deficiency: Metachromatic Leukodystrophy, ARSA Deficiency". GeneReviews, 2006
- Fluharty, Arvan. "Arylsulfatase A Deficiency: Metachromatic Leukodystrophy, ARSA Deficiency". GeneReviews, 2006
- Blomqvist, M.; Gieselmann, V.; Månsson, J. E. (2011). "Accumulation of lysosulfatide in the brain of arylsulfatase A-deficient mice". Lipids in Health and Disease 10 (1): 28. doi:10.1186/1476-511X-10-28. PMC 3041674. PMID 21299873.
- Hohenschutz, C; Eich P; Friedl W; Waheed A; Conzelmann E; Propping P. (April 1989). "Pseudodeficiency of arylsulfatase A". Human Genetics 45–8 (1): 45–8. PMID 2565866. Retrieved 2012-09-30.
- Herz, Barbara; Bach, G. (1984). HUMAN GENETICS 66: 147–150 http://www.springerlink.com/content/r705070311k44512/
|url=missing title (help). Retrieved 2012-09-30.
- Metachromatic leukodystrophy at Genetics Home Reference. Reviewed September 2007
- MLD Registry http://www.MLDregistry.org
- Biffi A, Lucchini G, Rovelli A, Sessa M (October 2008). "Metachromatic leukodystrophy: an overview of current and prospective treatments". Bone Marrow Transplant. 42 Suppl 2: S2–6. doi:10.1038/bmt.2008.275. PMID 18978739.
- Biffi, A.; Montini, E.; Lorioli, L.; Cesani, M.; Fumagalli, F.; Plati, T.; Baldoli, C.; Martino, S.; Calabria, A.; Canale, S.; Benedicenti, F.; Vallanti, G.; Biasco, L.; Leo, S.; Kabbara, N.; Zanetti, G.; Rizzo, W. B.; Mehta, N. A. L.; Cicalese, M. P.; Casiraghi, M.; Boelens, J. J.; Del Carro, U.; Dow, D. J.; Schmidt, M.; Assanelli, A.; Neduva, V.; Di Serio, C.; Stupka, E.; Gardner, J.; Von Kalle, C. (2013). "Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy". Science 341 (6148): 1233158. doi:10.1126/science.1233158. PMID 23845948.
- Inclusion criteria, Therapy Description & Contact information
- "GSK Product Pipeline". GSK. March 2014. Retrieved 29 June 2014.
- EU/3/10/813 European Commission orphan designation EU/3/10/813 issued 26-November-2010
- FDA/OOPD issued 27-February-2008
Some portions of this article are courtesy of the public domain text available at the National Institute of Neurological Disorders and Stroke:
- "NINDS Metachromatic Leukodystrophy Information Page". Retrieved 2009-06-07.
MLD Specific Global Organizations:
Leukodystrophy & Lysosomal Disease Organizations:
- Australian Leukodystrophy Support Group (Australia)
- Bethany's Hope (Canada)
- ELA, The European Leukodystrophy Association
- The Evanosky Foundation
- Hide & Seek Foundation for Lysosomal Disease Research
- New Zealand Organisation for Rare Disorders
- The Stennis Foundation
- Further information regarding MLD, treatments, genetics, and current research projects, can be found at:
- Other Links: